Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
$0.59
+64.3%
$0.35
$0.22
$15.80
$29.22M0.799.84 million shs466.15 million shs
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$0.94
+1.1%
$1.12
$0.87
$2.55
$17.73M0.52228,330 shs90,117 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$4.71
$6.43
$1.78
$10.40
N/A1.4527,886 shs11,029 shs
VIVS
VivoSim Labs
$1.81
+2.3%
$1.77
$1.41
$21.96
$4.71M0.94370,612 shs17,773 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
0.00%+6.85%+0.28%+35,899,900.00%+35,899,900.00%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
0.00%-4.11%-17.70%-33.09%-16.22%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00%-7.10%-25.65%-27.54%+132.02%
VIVS
VivoSim Labs
0.00%+1.43%-6.35%+176,999,900.00%+176,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.4564 of 5 stars
3.55.00.00.03.11.70.6
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
1.1881 of 5 stars
0.05.00.00.04.10.00.0
VIVS
VivoSim Labs
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
0.00
N/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50791.92% Upside
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00
N/AN/AN/A
VIVS
VivoSim Labs
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/AN/AN/AN/A($2.17) per shareN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$7.81MN/AN/AN/A$2.45 per shareN/A
VIVS
VivoSim Labs
$140K32.50N/AN/A$5.54 per share0.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
-$12.54MN/A0.00N/AN/AN/A-737.96%N/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$13.94M-$0.59N/AN/AN/AN/A-88.15%-70.00%8/20/2025 (Estimated)
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$6.94M-$2.17N/AN/A-122.46%-97.25%-88.96%11/6/2025 (Estimated)
VIVS
VivoSim Labs
-$2.48M-$10.20N/AN/A-1,396.48%-32.95%-21.31%N/A

Latest VIVS, PULM, ASBP, and CMMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.09+$0.11-$0.09N/AN/A
8/13/2025Q2 2025
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/A-$0.04N/A-$0.04N/AN/A
8/12/2025Q1 2026
VIVS
VivoSim Labs
N/A-$1.14N/A-$1.14N/A$0.04 million
8/6/2025Q2 2025
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.42N/A-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
VIVS
VivoSim Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/A
0.09
0.09
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
5.33
5.33
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
11.21
11.21
VIVS
VivoSim Labs
N/A
4.52
4.52

Institutional Ownership

CompanyInstitutional Ownership
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
19.17%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
46.05%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%
VIVS
VivoSim Labs
8.23%

Insider Ownership

CompanyInsider Ownership
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
48.00%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
11.91%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
VIVS
VivoSim Labs
3.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/A49.53 million25.75 millionN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2018.86 million16.61 millionNot Optionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
20N/AN/ANot Optionable
VIVS
VivoSim Labs
202.60 million2.50 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aspire Biopharma stock logo

Aspire Biopharma NASDAQ:ASBP

$0.59 +0.23 (+64.35%)
As of 04:00 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$0.94 +0.01 (+1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.94 +0.00 (+0.21%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$4.76 +0.05 (+0.98%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

VivoSim Labs NASDAQ:VIVS

$1.81 +0.04 (+2.26%)
As of 03:59 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.